MedTrace Logo

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

NCT02763566 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 463

Last updated 2026-02-05

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.

Conditions

Interventions

DRUG

Abemaciclib

Administered orally

DRUG

Anastrozole

Administered orally

DRUG

Letrozole

Administered orally

DRUG

Placebo

Administered orally

DRUG

Fulvestrant

Administered intramuscularly

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-05
Primary Completion
2019-03-29
Completion
2028-03-31

Countries

  • Brazil
  • China
  • India
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02763566 on ClinicalTrials.gov